Elinzanetant is an investigational dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist currently in clinical development for the treatment of moderate to severe vasomotor symptoms associated… Read more
![Chemical structure of ((7S,9aS)-Octahydropyrazino[2,1-c][1,4]oxazin-7-yl)methanol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F929047-53-0-7S9aS-Octahydropyrazino21-c14oxazin-7-ylmethanol.png&w=3840&q=75)
![Chemical structure of (7R,9aR)-7-(((tert-Butyldimethylsilyl)oxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F929048-24-8-7R9aR-7-tert-Butyldimethylsilyloxymethyloctahydropyrazino21-c14oxazine.png&w=3840&q=75)
![Chemical structure of (7R,9aS)-7-(((tert-Butyldimethylsilyl)oxy)methyl)-8-nitrosooctahydropyrazino[2,1-c][1,4]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F7R9aS-7-tert-Butyldimethylsilyloxymethyl-8-nitrosooctahydropyrazino21-c14oxazine.png&w=3840&q=75)
![Chemical structure of (7R,9aS)-7-(((tert-Butyldimethylsilyl)oxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F7R9aS-7-tert-Butyldimethylsilyloxymethyloctahydropyrazino21-c14oxazine.png&w=3840&q=75)
![Chemical structure of (7S,9aR)-7-(((tert-Butyldimethylsilyl)oxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F929047-31-4-7S9aR-7-tert-Butyldimethylsilyloxymethyloctahydropyrazino21-c14oxazine.png&w=3840&q=75)
![Chemical structure of (7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1268364-45-9-7S9aS-7-Benzyloxymethyloctahydropyrazino21-c14oxazine.png&w=3840&q=75)
![Chemical structure of (7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine Dioxalate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1268364-46-0-7S9aS-7-Benzyloxymethyloctahydropyrazino21-c14oxazine-Dioxalate.png&w=3840&q=75)

![Chemical structure of 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7R,9aR)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethylpropanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F929047-01-8-2-35-Bistrifluoromethylphenyl-N-4-4-fluoro-2-methylphenyl-6-7R9aR-7-hydroxymethylhexahydropyrazino21-c14oxazin-81H-ylpyridin-3-yl-N2-dimet.png&w=3840&q=75)
![Chemical structure of 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7R,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethylpropanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-35-Bistrifluoromethylphenyl-N-4-4-fluoro-2-methylphenyl-6-7R9aS-7-hydroxymethylhexahydropyrazino21-c14oxazin-81H-ylpyridin-3-yl-N2-dimethylpropanami.png&w=3840&q=75)
![Chemical structure of 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aR)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethylpropanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F929046-35-5-2-35-Bistrifluoromethylphenyl-N-4-4-fluoro-2-methylphenyl-6-7S9aR-7-hydroxymethylhexahydropyrazino21-c14oxazin-81H-ylpyridin-3-yl-N2-dimet.png&w=3840&q=75)

![Chemical structure of 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(6-((7R,9aR)-7-(((tert-butyldimethylsilyl)oxy)methyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl)-N,2-dimethylpropanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F929048-27-1-2-35-Bistrifluoromethylphenyl-N-6-7R9aR-7-tert-butyldimethylsilyloxymethylhexahydropyrazino21-c14oxazin-81H-yl-4-4-fluoro-2-methylphenylpy.png&w=3840&q=75)








![Chemical structure of 7-(((tert-Butyldimethylsilyl)oxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F7-tert-Butyldimethylsilyloxymethyloctahydropyrazino21-c14oxazine.png&w=3840&q=75)



















Elinzanetant is an investigational dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist currently in clinical development for the treatment of moderate to severe vasomotor symptoms associated with menopause. This category offers high-quality reference standards essential for the comprehensive analytical support of this active pharmaceutical ingredient. Laboratories utilize these materials for impurity profiling, ensuring the identification and quantification of synthetic byproducts, degradation products, and stereoisomers throughout the manufacturing process. The collection also includes pharmacopeial and non-pharmacopeial impurities, alongside relevant metabolites, which are critical for rigorous method validation. Additionally, researchers rely on stable isotope-labelled compounds as internal standards for accurate mass spectrometry-based quantification. By providing these specialized materials, the catalog enables precise quality control and regulatory compliance in the development and characterization of this novel therapeutic agent.